CG
NVCR icon

Caprock Group’s NovoCure NVCR Stock Holding History

Caprock Group’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$442K Buy
29,174
+7,725
+36% +$117K 0.01% 896
2026
Q1 		$234K Sell
21,449
-90,097
-81% -$1.13M 0.01% 1003
2025
Q4 		$1.44M Buy
+111,546
New +$1.43M 0.03% 487
2025
Q1 		$691K Buy
+38,794
New +$881K 0.02% 598

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Caprock Group's NVCR Position: Q2 2026 in Review

Caprock Group increased its NovoCure (NVCR) stake by 36% in Q2 2026, buying an estimated $117K and bringing the position to 29,174 shares worth $442K. The position accounts for 0.01% of the portfolio, ranked #896.

Caprock Group first reported a position in NVCR in Q1 2025 and has held it in 4 quarters since. The position peaked at $1.44M in Q4 2025. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Caprock Group held 29,174 shares of NovoCure worth $442K as of Q2 2026.
  • Caprock Group bought 7,725 NovoCure shares in Q2 2026, an estimated $117K.
  • NovoCure made up 0.01% of Caprock Group's portfolio in Q2 2026, its #896 holding.
  • Caprock Group first reported a position in NovoCure in Q1 2025 and has held it in 4 quarters since.
  • Caprock Group's NovoCure position peaked at $1.44M in Q4 2025.
  • 218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Caprock Group's 13F filing for Q2 2026, filed 27 Jul 2026.